Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Shares Issued (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Shares Issued for 13 consecutive years, with $405000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 40.44% year-over-year to $405000.0, compared with a TTM value of $1.1 million through Dec 2025, up 14.94%, and an annual FY2025 reading of $761000.0, down 47.59% over the prior year.
  • Shares Issued was $405000.0 for Q4 2025 at Karyopharm Therapeutics, down from $680000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $2.1 million in Q2 2021 and bottomed at $11000.0 in Q3 2022.
  • Average Shares Issued over 5 years is $827583.3, with a median of $816500.0 recorded in 2021.
  • The sharpest move saw Shares Issued plummeted 98.71% in 2021, then surged 157.58% in 2024.
  • Year by year, Shares Issued stood at $896000.0 in 2021, then rose by 29.91% to $1.2 million in 2022, then tumbled by 77.32% to $264000.0 in 2023, then soared by 157.58% to $680000.0 in 2024, then crashed by 40.44% to $405000.0 in 2025.
  • Business Quant data shows Shares Issued for KPTI at $405000.0 in Q4 2025, $680000.0 in Q4 2024, and $264000.0 in Q4 2023.